Cargando…
Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study
BACKGROUND: The aim of the study was to determine the maximal tolerated dose (MTD) of gemcitabine every two weeks concurrent to radiotherapy, administered during an aggressive program of sequential and simultaneous radiochemotherapy for locally advanced, unresectable non-small cell lung cancer (NSCL...
Autores principales: | Gagel, Bernd, Piroth, Marc, Pinkawa, Michael, Reinartz, Patrick, Krohn, Thomas, Kaiser, Hans J, Stanzel, Sven, Breuer, Christian, Asadpour, Branka, Schmachtenberg, Axel, Eble, Michael J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931600/ https://www.ncbi.nlm.nih.gov/pubmed/17598906 http://dx.doi.org/10.1186/1471-2407-7-112 |
Ejemplares similares
-
Sequencing chemotherapy and radiotherapy in locoregional advanced breast cancer patients after mastectomy – a retrospective analysis
por: Piroth, Marc D, et al.
Publicado: (2008) -
[(18)F] fluoromisonidazole and [(18)F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study
por: Gagel, Bernd, et al.
Publicado: (2006) -
pO polarography, contrast enhanced color duplex sonography (CDS), [(18)F] fluoromisonidazole and [(18)F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?
por: Gagel, Bernd, et al.
Publicado: (2007) -
Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment
por: Pinkawa, Michael, et al.
Publicado: (2009) -
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)